T. Rowe Price Associates
AGL icon

T. Rowe Price Associates’s Agilon Health AGL Stock Holding History

T. Rowe Price Associates’s Portfolio AGL Stock Details AGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.25M Buy
+11,606
New +$760K ﹤0.01% 2222
2026
Q1 		– Sell
-6,678
Closed -$114K – 3133
2025
Q4 		$114K Sell
6,678
-1,664
-20% -$32.3K ﹤0.01% 2927
2025
Q3 		$215K Sell
8,342
-5,371
-39% -$203K ﹤0.01% 2765
2025
Q2 		$790K Sell
13,713
-283
-2% -$22.7K ﹤0.01% 2088
2025
Q1 		$1.52M Buy
13,996
+455
+3% +$39.6K ﹤0.01% 1741
2024
Q4 		$644K Buy
13,541
+3,935
+41% +$238K ﹤0.01% 2172
2024
Q3 		$945K Sell
9,606
-32,023
-77% -$4.13M ﹤0.01% 1994
2024
Q2 		$6.81M Sell
41,629
-25,001
-38% -$3.56M ﹤0.01% 1169
2024
Q1 		$10.2M Sell
66,630
-338,965
-84% -$56.4M ﹤0.01% 1104
2023
Q4 		$127M Buy
405,595
+127,803
+46% +$46.3M 0.02% 500
2023
Q3 		$123M Buy
277,792
+122,124
+78% +$55.2M 0.02% 475
2023
Q2 		$67.5M Buy
155,668
+63,508
+69% +$35.7M 0.01% 621
2023
Q1 		$54.7M Buy
92,160
+63,617
+223% +$35.6M 0.01% 662
2022
Q4 		$11.5M Sell
28,543
-6,373
-18% -$2.99M ﹤0.01% 1028
2022
Q3 		$20.4M Sell
34,916
-94,009
-73% -$56.3M ﹤0.01% 895
2022
Q2 		$70.4M Sell
128,925
-7,508
-6% -$3.8M 0.01% 770
2022
Q1 		$86.5M Sell
136,433
-27,956
-17% -$14.4M 0.01% 779
2021
Q4 		$111M Sell
164,389
-20,616
-11% -$12.5M 0.01% 730
2021
Q3 		$121M Buy
185,005
+9,821
+6% +$8.39M 0.01% 701
2021
Q2 		$178M Buy
+175,184
New +$153M 0.02% 597

Other funds holding AGL

CDR
Clayton Dubilier & Rice New York $895M AUM 792.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
NPCM
North Peak Capital Management New York $900M AUM 193.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCP
Durable Capital Partners Bethesda, Maryland $10.3B AUM 29.04% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

T. Rowe Price Associates's AGL Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in Agilon Health (AGL) in Q2 2026: 11,606 shares worth $1.25M. The stake represents ﹤0.01% of the portfolio and ranks #2222 among its holdings. This is a return to the name: T. Rowe Price Associates previously reported a position in AGL as recently as Q4 2025.

T. Rowe Price Associates first reported a position in AGL in Q2 2021 and has held it in 20 quarters since. The position peaked at $178M in Q2 2021. 179 funds tracked by Wall St. Rank hold AGL as of Q2 2026.

  • T. Rowe Price Associates held 11,606 shares of Agilon Health worth $1.25M as of Q2 2026.
  • Agilon Health was a new T. Rowe Price Associates position in Q2 2026.
  • Agilon Health made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2222 holding.
  • T. Rowe Price Associates first reported a position in Agilon Health in Q2 2021 and has held it in 20 quarters since.
  • T. Rowe Price Associates's Agilon Health position peaked at $178M in Q2 2021.
  • 179 funds tracked by Wall St. Rank held Agilon Health as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.